KPV Peptide: Anti-Inflammatory Research Without Immune Suppression
KPV (Lysine-Proline-Valine) is a tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino acid neuropeptide produced by the pituitary gland and various immune cells. Despite being only three amino acids long, KPV retains the full anti-inflammatory potency of the parent hormone — and in some assays, exceeds it — while lacking α-MSH’s pigmentation-altering effects.
What makes KPV unique in the anti-inflammatory landscape is its selectivity: it suppresses excessive inflammation without broadly suppressing immune function. Most pharmaceutical anti-inflammatories (corticosteroids, NSAIDs, immunosuppressants) achieve their effects by dampening the immune system as a whole. KPV targets specific inflammatory pathways while leaving immune defense mechanisms intact.
Chemical Profile
Sequence: Lysine-Proline-Valine (Lys-Pro-Val) | Molecular Weight: 342.43 Da | CAS: 67727-97-3 | Parent molecule: α-Melanocyte-Stimulating Hormone (α-MSH, positions 11-13) | Classification: Melanocortin-derived anti-inflammatory peptide
Mechanisms of Action
NF-κB Pathway Suppression
KPV’s primary anti-inflammatory mechanism is suppression of Nuclear Factor kappa-B (NF-κB) — one of the most important transcription factors in inflammatory biology. NF-κB acts as a master switch that controls the expression of dozens of pro-inflammatory genes. When activated, it drives production of TNF-α, IL-6, IL-1β, nitric oxide, and other inflammatory mediators.
Published research (2012, International Journal of Physiology, Pathophysiology and Pharmacology) demonstrated that KPV suppresses NF-κB activation, reducing downstream expression of inflammatory genes. This is mechanistically distinct from how BPC-157 (nitric oxide modulation) or GHK-Cu (cytokine reduction) address inflammation — making KPV a non-redundant addition in multi-peptide research protocols.
Pro-Inflammatory Cytokine Reduction
KPV significantly downregulates TNF-α — a major pro-inflammatory cytokine encoded by the TNFA gene that uses the NF-κB pathway. A 2017 mouse model study observed significant TNF-α downregulation following KPV administration. KPV also reduces IL-6 and IL-1β secretion in activated immune cells and keratinocytes, providing broad cytokine-level inflammation control.
Antimicrobial Activity
Published research in the Journal of Leukocyte Biology (Cutuli et al., 2000) demonstrated that KPV significantly inhibits colony formation of Staphylococcus aureus and reduces viability and germ tube formation of Candida albicans — even at physiological (picomolar) concentrations.
Critically, the researchers found that KPV did not reduce neutrophil killing capacity. Most anti-inflammatory drugs decrease the body’s ability to fight pathogens as a side effect of dampening immune function. KPV achieves anti-inflammatory effects while preserving — and actually enhancing — antimicrobial defense. The researchers concluded that this dual action could be useful in conditions where infection and inflammation coexist.
Skin Protection
A 2025 study published in ScienceDirect investigated KPV’s protective effects against PM10 (particulate matter) damage in human keratinocytes. KPV treatment restored cell viability, reduced IL-1β secretion, inhibited ROS (reactive oxygen species) production, and decreased apoptosis-related protein expression. In a 3D skin model, KPV effectively attenuated inflammatory cell death induced by environmental pollutants.
Gut Inflammation Research
KPV has demonstrated significant anti-inflammatory effects in preclinical colitis models. A notable finding is that KPV can be delivered orally via the PepT1 intestinal transporter (Dalmasso et al., 2008, Gastroenterology) — unusual for a peptide, as most are degraded in the GI tract. This oral bioavailability makes KPV particularly relevant for gut inflammation research. Hyaluronic acid-functionalized nanoparticles loaded with KPV have been shown to accelerate mucosal healing and reduce TNF-α in inflamed colonic tissue.
No Melanogenesis
Unlike full-length α-MSH and melanocortin analogs like Melanotan II, KPV does not activate MC1R melanocortin receptors responsible for melanin production. Its activity is limited to anti-inflammatory and immunomodulatory effects with no skin darkening side effects. This selectivity is one of the primary reasons researchers prefer KPV over full-length α-MSH for anti-inflammatory studies.
KPV in the KLOW Blend
KPV is the component that distinguishes PSPeptides’ KLOW blend from the GLOW blend. GLOW contains BPC-157, GHK-Cu, and TB-500 — covering angiogenesis, collagen synthesis, and cell migration. KLOW adds KPV to provide NF-κB-mediated anti-inflammatory control and antimicrobial activity — pathways not covered by the other three components.
| Feature | GLOW ($79.99) | KLOW ($129.99) |
|---|---|---|
| BPC-157 (10mg) | ✓ | ✓ |
| GHK-Cu (50mg) | ✓ | ✓ |
| TB-500 (10mg) | ✓ | ✓ |
| KPV (10mg) | — | ✓ |
| NF-κB suppression | — | ✓ |
| Antimicrobial activity | — | ✓ |
Frequently Asked Questions
Does KPV cause skin darkening?
No. KPV does not activate MC1R melanocortin receptors responsible for melanin production. Unlike Melanotan II or full-length α-MSH, KPV’s activity is limited to anti-inflammatory and immunomodulatory effects.
How is KPV different from BPC-157 for inflammation?
They target different inflammatory pathways. KPV suppresses NF-κB — a master transcription factor controlling inflammatory gene expression. BPC-157 modulates the nitric oxide system. These are complementary, non-redundant mechanisms, which is why they’re combined in the KLOW blend.
Can KPV be taken orally?
Published research demonstrates that KPV can be absorbed via the PepT1 intestinal transporter, giving it oral bioavailability — unusual for a peptide. This makes it particularly relevant for gut inflammation research applications.
References
- Brzoska T, et al. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2008;67(Suppl 3):iii49-iii55.
- Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134:166-178.
All products are intended for laboratory research use only. Not for human consumption.
PSPeptides — US Made & Shipped | Third-Party Tested | 99%+ Purity | Same-Day Shipping